Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   MDxHealth   /   koers MDxHealth naar 15,25 en later naar 47 euro

koers MDxHealth naar 15,25 en later naar 47 euro

Volgen
1.073 Posts
Pagina: «« 1 ... 17 18 19 20 21 ... 54 »» | Laatste | Omlaag ↓
  3. [verwijderd] 6 november 2015 16:46
    Volgende week gaat Jan Groen de koers van MdxHealth aanjagen;

    4th KBC Securities Benelux Biotech & Healthcare Seminar
    Date: Tuesday, November 10, 2015
    Location: Convene Conference Center, 101 Park Avenue, New York

    9th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
    Date: Thursday, November 19, 2015, 4:00 PM Eastern Time
    Location: Westin Grand Central, New York City
    A live webcast of this presentation will be available at the Investor tab of the MDxHealth website at mdxhealth.com/share-data.
  7. [verwijderd] 6 november 2015 17:04
    quote:

    inspirator schreef op 6 november 2015 16:46:

    Volgende week gaat Jan Groen de koers van MdxHealth aanjagen;

    4th KBC Securities Benelux Biotech & Healthcare Seminar
    Date: Tuesday, November 10, 2015
    Location: Convene Conference Center, 101 Park Avenue, New York

    9th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
    Date: Thursday, November 19, 2015, 4:00 PM Eastern Time
    Location: Westin Grand Central, New York City
    A live webcast of this presentation will be available at the Investor tab of the MDxHealth website at mdxhealth.com/share-data.
    Jan heeft zijn koffer al gepakt.

    mdxHealth 15 euro yes we can
  8. [verwijderd] 7 november 2015 19:49
    GSA capital is de enigste shortpartij in MdxHealth

    Deze positie is opgebouwd in augustus, september en oktober.

    De koers van MdxHealth in deze periode begaf zich tussen 4,60 en 3,85.

    Dit is dan ook de reden dat koers even niet boven 4,20 euro kwam.

    Maar men wil graag short positie sluiten tot koers van 4,20 euro.

    GSA capital wil graag shorts sluiten met winst.

    Wordt tijd dat er een short squeeze komt; GSA capital zal shortpositie met koers van 4,50 euro langzaam sluiten en met koers van 15 euro snel !

  9. [verwijderd] 9 november 2015 08:20
    De steile klim naar koers MdxHealth van 15 euro wordt ingezet.
    GSA capital is het haasje.

    Prospective Clinical Validation Study with AssureMDx for Bladder Cancer

    Study to Evaluate Ability to Reduce Invasive Procedures for Bladder Cancer Survivors and Allow Earlier Detection of Recurrence


    2 0 0 2
    November 09, 2015 01:08 ET | Source: MdxHealth (TM)
    IRVINE, Calif. and HERSTAL, Belgium, Nov. 9, 2015 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext: MDXH), announced today that it has entered into an agreement with Erasmus University Medical Center Rotterdam (Erasmus MC) for the inclusion of MDxHealth's AssureMDx for Bladder Cancer, a urine-based, liquid biopsy test, into a prospective clinical study designed to assess the ability of urine-based molecular tests to stratify patients with non-muscle invasive bladder cancer (NMIBC) for recurrence monitoring.

    A total of 2,000 urine samples from 435 patients will be collected in a, multi-center, two-arm, prospective randomized clinical trial financed by ZonMw, the Netherlands Organisation for Health Research and Development and Erasmus MC. The study is designed to assess the test's ability to safely reduce the number of invasive cystoscopies performed during follow-up of patients with NMIBC with a low/intermediate risk of recurrence or progression. The study will also examine whether the addition of urine tests to follow-up of patients with higher risk of recurrence and progression leads to earlier detection of potentially dangerous recurrences. All urine samples will be tested using AssureMDx assay.

    Prof. Dr. Ellen Zwarthoff, principal investigator at Erasmus MC commented, "Given that current diagnostic tools are invasive and at times costly, the potential for urine-based molecular tests to help reduce the number of invasive cystoscopies for low or intermediate risk patients, while providing earlier detection of possible recurrence for those at high-risk, would be a major advance for patient care. As such, we look forward to collaborating with MDxHealth on this important clinical trial."

    About Bladder Cancer

    In the US and EU, over 170,000 patients are diagnosed with bladder cancer every year, and over 50,000 patients will die from the disease. Annually in the US alone, it is estimated that over 1 million patients with hematuria (blood in urine) are referred to urologists for fear of bladder cancer. The traditional tools and procedures employed for the detection of bladder cancer have some limitations, not the least of which are cost and invasiveness, but also these methodologies are prone to miss some small bladder tumors, satellite lesions as well as carcinoma in situ. Importantly, bladder cancer is one of the most expensive cancers to treat given more than half of all early stage bladder cancer patients will recur in the three years following treatment.

    About Erasmus University Medical Center

    Erasmus MC is the largest and most authoritative University Medical Center in the Netherlands. Almost 13,000 staff members work within the core tasks of patient care, education, and scientific research on the continuous improvement and enhancement of individual patient care and social healthcare. They develop high-level knowledge, pass this on to future professionals, and apply it in everyday patient care.

    About MDxHealth

    MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

    For more information:

    Dr. Jan Groen, CEO
    MDxHealth
    US: +1 949 812 6979
    BE: +32 4 364 20 70
    info@mdxhealth.com





    Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
    Consilium Strategic Communications
    UK: +44 20 3709 5701
    Cell: + 44 7739658783
    mdxhealth@consilium-comms.com
    - See more at: globenewswire.com/news-release/2015/1...
  10. [verwijderd] 10 november 2015 08:04
    quote:

    inspirator schreef op 7 november 2015 19:49:

    GSA capital is de enigste shortpartij in MdxHealth

    Deze positie is opgebouwd in augustus, september en oktober.

    De koers van MdxHealth in deze periode begaf zich tussen 4,60 en 3,85.

    Dit is dan ook de reden dat koers even niet boven 4,20 euro kwam.

    Maar men wil graag short positie sluiten tot koers van 4,20 euro.

    GSA capital wil graag shorts sluiten met winst.

    Wordt tijd dat er een short squeeze komt; GSA capital zal shortpositie met koers van 4,50 euro langzaam sluiten en met koers van 15 euro snel !

    Als Marc Coucke zijn positie komende week verdubbeld, dan is de shortsqueeze een feit.

    zonder moeite deze week nog koersverdubbeling MdxHealth

1.073 Posts
Pagina: «« 1 ... 17 18 19 20 21 ... 54 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum